The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic factors of multidisciplinary treatment for borderline resectable and locally advanced pancreatic adenocarcinoma: Results of a dual-center study.
 
Nana Kimura
No Relationships to Disclose
 
Takamichi Igarashi
No Relationships to Disclose
 
Suguru Yamada
No Relationships to Disclose
 
Kenta Murotani
No Relationships to Disclose
 
Isaku Yoshioka
No Relationships to Disclose
 
Hideki Takami
No Relationships to Disclose
 
Kazuto Shibuya
No Relationships to Disclose
 
Masamichi Hayashi
No Relationships to Disclose
 
Haruyoshi Tanaka
No Relationships to Disclose
 
Katsuhisa Hirano
No Relationships to Disclose
 
Toru Watanabe
No Relationships to Disclose
 
Nobutake Tanaka
No Relationships to Disclose
 
Hayato Baba
No Relationships to Disclose
 
Yuuko Tohmatsu
No Relationships to Disclose
 
Ayano Sakai
No Relationships to Disclose
 
Mina Fukasawa
No Relationships to Disclose
 
Koshi Matsui
No Relationships to Disclose
 
Tomoyuki Okumura
No Relationships to Disclose
 
Yasuhiro Kodera
Honoraria - Abbvie; Amgen; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Lilly Japan; Miyarisan Pharmaceutical; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - Daii Sankyo
Research Funding - abbott Japan (Inst); Bayer (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Otsuka (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); TOA Pharmaceuticals (Inst); Tsumura & Co. (Inst)
 
Tsutomu Fujii
Honoraria - Asahi Kasei; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; EA Pharma; Johnson & Johnson; Kaken Pharmaceutical; Lilly; Miyarisan pharmaceutical; Otsuka; Taiho Pharmaceutical; TERUMO; Tsumura & Co.
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Covidien/Medtronic (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Otsuka (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TERUMO (Inst); Tsumura & Co. (Inst)